MX2019011782A - Derivados de acido ciclilo-acetico sustituido para el tratamiento de enfermedades metabolicas. - Google Patents
Derivados de acido ciclilo-acetico sustituido para el tratamiento de enfermedades metabolicas.Info
- Publication number
- MX2019011782A MX2019011782A MX2019011782A MX2019011782A MX2019011782A MX 2019011782 A MX2019011782 A MX 2019011782A MX 2019011782 A MX2019011782 A MX 2019011782A MX 2019011782 A MX2019011782 A MX 2019011782A MX 2019011782 A MX2019011782 A MX 2019011782A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- acetic acid
- acid derivatives
- metabolic disorders
- substituted cyclyl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title 1
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 2
- 229940125827 GPR40 agonist Drugs 0.000 abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000000580 secretagogue effect Effects 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- -1 aromatic ring compound Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017072813 | 2017-03-31 | ||
| PCT/JP2018/014501 WO2018182050A1 (en) | 2017-03-31 | 2018-03-29 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019011782A true MX2019011782A (es) | 2020-02-10 |
Family
ID=62116518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011782A MX2019011782A (es) | 2017-03-31 | 2018-03-29 | Derivados de acido ciclilo-acetico sustituido para el tratamiento de enfermedades metabolicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10968231B2 (enExample) |
| EP (1) | EP3601260A1 (enExample) |
| JP (1) | JP2020512387A (enExample) |
| KR (1) | KR20190136049A (enExample) |
| CN (1) | CN110678458A (enExample) |
| AR (1) | AR111199A1 (enExample) |
| CA (1) | CA3058588C (enExample) |
| MX (1) | MX2019011782A (enExample) |
| TW (1) | TW201841920A (enExample) |
| WO (1) | WO2018182050A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11186565B2 (en) | 2017-03-31 | 2021-11-30 | Takeda Pharmaceutical Company Limited | Aromatic compound |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP3978485B1 (en) | 2019-05-31 | 2026-02-11 | Hyundai Pharm Co., Ltd. | Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| TWI894280B (zh) * | 2020-05-26 | 2025-08-21 | 南韓商愛思阿爾法數字醫療科技有限公司 | 用以治療癌症惡病質之系統、用以治療癌症惡病質之運算系統及其操作方法、以及非暫態電腦可讀取媒體 |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN112830933A (zh) * | 2021-02-04 | 2021-05-25 | 康化（上海）新药研发有限公司 | 一种3,4-二氢-2H-吡喃并[2,3-b]吡啶合成方法 |
| KR102699076B1 (ko) * | 2021-04-01 | 2024-08-27 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
| JPWO2023106310A1 (enExample) * | 2021-12-07 | 2023-06-15 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2007225208A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| JP5591706B2 (ja) | 2007-10-10 | 2014-09-17 | アムジエン・インコーポレーテツド | 置換ビフェニルｇｐｒ４０調節因子 |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| JP2013523819A (ja) * | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| WO2013122029A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
| ES2672992T3 (es) | 2013-08-09 | 2018-06-19 | Takeda Pharmaceutical Company Limited | Compuesto aromático |
| US9920040B2 (en) | 2015-08-12 | 2018-03-20 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
| WO2017027310A1 (en) | 2015-08-12 | 2017-02-16 | Janssen Pharmaceutica Nv | Gpr40 agonists for the treatment of type ii diabetes |
| US9856245B2 (en) | 2015-08-12 | 2018-01-02 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
| JP6627397B2 (ja) | 2015-10-09 | 2020-01-08 | 富士通オプティカルコンポーネンツ株式会社 | 光モジュール及び光伝送装置 |
| EP3436003B1 (en) | 2016-03-29 | 2023-08-23 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
| WO2018081047A1 (en) | 2016-10-25 | 2018-05-03 | Janssen Pharmaceutica Nv | Cyclohexyl gpr40 agonists for the treatment of type ii diabetes |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US11186565B2 (en) | 2017-03-31 | 2021-11-30 | Takeda Pharmaceutical Company Limited | Aromatic compound |
-
2018
- 2018-03-28 AR ARP180100764A patent/AR111199A1/es unknown
- 2018-03-29 KR KR1020197032237A patent/KR20190136049A/ko not_active Abandoned
- 2018-03-29 EP EP18722743.4A patent/EP3601260A1/en not_active Withdrawn
- 2018-03-29 MX MX2019011782A patent/MX2019011782A/es unknown
- 2018-03-29 TW TW107110982A patent/TW201841920A/zh unknown
- 2018-03-29 US US16/497,141 patent/US10968231B2/en not_active Expired - Fee Related
- 2018-03-29 JP JP2019554000A patent/JP2020512387A/ja not_active Ceased
- 2018-03-29 WO PCT/JP2018/014501 patent/WO2018182050A1/en not_active Ceased
- 2018-03-29 CN CN201880023454.7A patent/CN110678458A/zh active Pending
- 2018-03-29 CA CA3058588A patent/CA3058588C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3601260A1 (en) | 2020-02-05 |
| KR20190136049A (ko) | 2019-12-09 |
| US10968231B2 (en) | 2021-04-06 |
| CA3058588A1 (en) | 2018-10-04 |
| JP2020512387A (ja) | 2020-04-23 |
| CN110678458A (zh) | 2020-01-10 |
| CA3058588C (en) | 2021-11-09 |
| TW201841920A (zh) | 2018-12-01 |
| WO2018182050A1 (en) | 2018-10-04 |
| US20200377509A1 (en) | 2020-12-03 |
| AR111199A1 (es) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120855T1 (el) | Αρωματικη ενωση | |
| SA521431209B1 (ar) | مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1 | |
| PH12016501582A1 (en) | Fused heterocyclic compound | |
| PH12016501614A1 (en) | Heterocyclic compound | |
| PH12022551119A1 (en) | New methylquinazolinone derivatives | |
| PH12019502248A1 (en) | Ip6k inhibitors | |
| UA94455C2 (en) | Oxadiazolidinedione compound | |
| MX354458B (es) | Compuesto de guanidina. | |
| WO2016172631A8 (en) | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof | |
| PH12021550449A1 (en) | 2,6-diamino pyridine compounds. | |
| PH12012502347A1 (en) | Bicyclic compound derivatives and their use as acc inhibitors | |
| WO2008102749A1 (ja) | 複素環化合物 | |
| EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
| AR111199A1 (es) | Compuesto aromático agonista de gpr40 | |
| ZA202100352B (en) | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | |
| MY181731A (en) | Azole benzene derivative | |
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| SG11201907240XA (en) | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | |
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| SG11201805791RA (en) | COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α | |
| JO3442B1 (ar) | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) | |
| SA522431572B1 (ar) | مركب بيريميدين-5-كربوكساميد | |
| WO2018060962A3 (en) | Metformin amino acid compounds and methods of using the same | |
| IN2013MU01124A (enExample) | ||
| MX2016014693A (es) | Derivados de pirazina. |